Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.The Lancet. Oncology|December 7, 2020
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialJonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al.Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.Frontiers in Oncology|November 16, 2020
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPERJonathan W Goldman, Julien Mazieres, Fabrice Barlesi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.Cancer Immunology Research|February 1, 2018
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single CenterAaron Lisberg, D Andrew Tucker, Jonathan W Goldman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients WithGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.Pageof 12